Retinitis pigmentosa

12 trials 5 recruiting MedDRA PT
12 Registered trials
5 Recruiting
11 Unique sponsors
14 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 10
H Endocrinology (ATC H) 1
S Ophthalmology/ENT (ATC S) 1
R Respiratory (ATC R) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Corticosteroid 2 substances
Phase III: 4 Phase II: 2 Phase I/II: 1 Phase I (Other): 1 Phase I (First in Human): 4

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

4 trials
  • Beacon Therapeutics (USA) Inc. Commercial
    ADENO-ASSOCIATED VIRUS VECTOR CONTAINING THE HUMAN RPGR GENE
    2024-511181-36-00 1 country n=5 Orphan
    Not authorised
  • Biogen Idec Research Limited Commercial
    TIMREPIGENE EMPARVOVEC
    2023-507994-16-00 2 countries 2024 n=54 Orphan
    Recruiting
  • Janssen - Cilag International Commercial
    BOTARETIGENE SPAROPARVOVEC
    2024-511411-25-00 6 countries 2022 n=31 Orphan
    Ended
  • Johns Hopkins University Academic
    ACETYLCYSTEINE
    2022-501438-46-00 3 countries 2024 n=120
    Ended

Phase II

2 trials
  • Laboratoires Thea Commercial
    ULTEVURSEN
    2024-515199-10-00 4 countries n=21 Orphan
    Not authorised
  • Laboratoires Thea Commercial
    ULTEVURSEN
    2024-515199-10-01 6 countries 2025 n=31 Orphan
    Recruiting

Phase I/II

1 trial
  • Gensight Biologics Commercial
    ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 2.7M8 CONTAINING THE CHRIMSONR-TDTOMATO GENE
    2024-516059-42-00 1 country 2017 n=9 Orphan
    Recruiting

Phase I (Other)

1 trial
  • Bioinova a.s. Commercial
    IMP not specified
    2023-503573-38-00 1 country n=10
    Pending

Phase I (First in Human)

4 trials
  • eyeDNA Therapeutics Commercial
    ADENOVIRUS ASSOCIATED VIRAL VECTOR SEROTYPE 5 CONTAINING THE HUMAN PDE6B GENE; ATROPINE SULFATE; DEXAMETHASONE PHOSPHATE; DEXAMETHASONE SODIUM PHOSPHATE, NEOMYCIN SULFATE; INDOMETACIN; PHENYLEPHRINE HYDROCHLORIDE, TROPICAMIDE
    2024-511687-90-00 1 country 2017 n=23 Orphan
    Ended
  • Novartis Pharma AG Commercial
    CPK850
    2023-508688-54-00 1 country 2018 n=21
    Ended
  • ViGeneron GmbH Commercial
    IMP not specified
    2023-504383-42-00 1 country 2025 n=6
    Recruiting
  • Centre D'Etude Des Cellules Souches Academic
    ISTEM-01
    2024-513662-18-00 1 country 2019 n=12
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Laboratoires Thea Commercial 2 Phase II 1
Bioinova a.s. Commercial 1 Phase I (Other) 0
Beacon Therapeutics (USA) Inc. Commercial 1 Phase III 0
Biogen Idec Research Limited Commercial 1 Phase III 1
Janssen - Cilag International Commercial 1 Phase III 0
eyeDNA Therapeutics Commercial 1 Phase I (First in Human) 0
Novartis Pharma AG Commercial 1 Phase I (First in Human) 0
ViGeneron GmbH Commercial 1 Phase I (First in Human) 1
Gensight Biologics Commercial 1 Phase I/II 1
Johns Hopkins University Academic 1 Phase III 0
Centre D'Etude Des Cellules Souches Academic 1 Phase I (First in Human) 1
New trials by year
2019
1
2022
1
2024
2
2025
2
← All indication landscapes